Rating Change
Wedbush reiterated its Neutral rating on Alto Neuroscience, Inc. (NYSE:ANRO) on August 13, 2026.
reiterateNYSE:ANRO
Wedbush Reiterates Neutral Rating on Alto Neuroscience, Inc. (ANRO)
Wedbush reiterated its Neutral rating on Alto Neuroscience, Inc. (NYSE:ANRO) on August 13, 2026.
At publication ·
What changed
Alto Neuroscience, Inc. (NYSE:ANRO) · reiterate
- Firm
- Wedbush
- Rating
- Neutral to Neutral
- Price at event
- $32.30
- Market capitalization
- $611.7M
At a glance
Key takeaways
- Wedbush reiterated a Neutral rating on Alto Neuroscience (ANRO) on August 13, 2026, with the stock trading at $32.30 and a market capitalization of $611.7 million.
- Among the 10 most recent analyst ratings, 8 are Buy, 2 are Hold, and 0 are Sell, indicating predominantly bullish sentiment despite Wedbush's Neutral stance.
Market Context
Alto Neuroscience, Inc. operates in the Healthcare sector. The stock currently trades at $32.30 with a market capitalization of $611.7M.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alto Neuroscience, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Alto Neuroscience, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Neutral | N/A |
| Aug 13, 2026 | BTIG | Buy | N/A |
| May 18, 2026 | Baird | Outperform | N/A |
| May 14, 2026 | Wedbush | Neutral | N/A |
| May 11, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ANRO Stock Page
Frequently Asked Questions
What does the Neutral rating mean for ANRO?
A rating of Neutral from Wedbush reflects the analyst's outlook on Alto Neuroscience, Inc. (NYSE:ANRO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ANRO forecast page.